FDA Expands Breast Cancer Treatment Options with Accelerated Approval of New Drug

The U.S. Food and Drug Administration (FDA) has announced the accelerated approval of Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for adult patients diagnosed with advanced breast cancer. This development signifies a significant step in providing new therapeutic avenues for individuals battling hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, particularly when resistance mutations emerge during prior treatments. The approval offers a targeted therapy designed to combat treatment resistance, potentially extending the time before disease progression.

The newly approved treatment targets estrogen receptor-1 (ESR1) mutations, which can develop as tumors evolve during treatment with aromatase inhibitors, a common initial therapy for advanced breast cancer. While these mutations are present in a small percentage of patients at the initial diagnosis of HR-positive metastatic breast cancer, their prevalence can rise significantly to nearly 40 percent after the disease progresses on an aromatase inhibitor. The accelerated approval pathway is utilized for drugs that address serious conditions and fulfill unmet medical needs, based on preliminary data. In this instance, the approval was contingent upon how long patients lived without their cancer worsening after the resistance mutation was detected in their blood. The FDA has mandated further studies to confirm the long-term clinical benefit of this treatment strategy.

The efficacy of Etcamah was assessed in a clinical trial that compared switching to Etcamah, an oral medication, in conjunction with a CDK4/6 inhibitor against continuing treatment with an aromatase inhibitor and a CDK4/6 inhibitor. Results from this trial indicated a median progression-free survival of 16 months for patients receiving Etcamah and a CDK4/6 inhibitor, compared to 9.2 months for those continuing with an aromatase inhibitor and a CDK4/6 inhibitor. To ensure accurate patient selection for this therapy, the FDA also authorized the Guardant360 CDx assay as a companion diagnostic. This test is crucial for identifying patients with breast cancer harboring ESR1 mutations who are suitable candidates for treatment with camizestrant.

The prescribing information for Etcamah includes important safety considerations. A boxed warning highlights the risk of irregular heart rhythms when Etcamah is administered concurrently with certain other medications. Additionally, warnings and precautions address concerns regarding abnormally slow heart rates and potential risks to an unborn baby. Full prescribing details for Etcamah will be made available on the Drugs@FDA platform. The Oncologic Drugs Advisory Committee had previously reviewed this application on April 30, 2026. The accelerated approval was granted to AstraZeneca, the pharmaceutical company responsible for developing Etcamah.

Article by Mel Anara, based upon information from the U.S. Food and Drug Administration

Video Spotlight